NASDAQ:ORIC

Oric Pharmaceuticals (ORIC) Stock Price, News & Analysis

Oric Pharmaceuticals logo
$7.36 -0.34 (-4.42%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$7.36 0.00 (0.00%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Oric Pharmaceuticals Stock (NASDAQ:ORIC)

Advanced

Key Stats

Today's Range
$7.28
▼
$8.00
50-Day Range
$7.36
▼
$13.85
52-Week Range
$7.23
▼
$14.68
Volume
1.46 million shs
Average Volume
1.97 million shs
Market Capitalization
$762.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.18
Consensus Rating
Moderate Buy

Company Overview

Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat.

The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.

Founded in 2014, Oric is headquartered in South San Francisco, California. It conducts research and clinical development of its drug candidates, with clinical studies involving patients in multiple regions.

AI Generated. May Contain Errors.

Oric Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

ORIC MarketRank™: 
2.71758934828 of 5 stars

Oric Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat, and ranked 422nd out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oric Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 13 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Oric Pharmaceuticals has a consensus price target of $20.18, representing about 174.2% upside from its current price of $7.36.

  • Amount of Analyst Coverage

    Oric Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Oric Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Oric Pharmaceuticals are expected to decrease in the coming year, from ($1.60) to ($1.88) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oric Pharmaceuticals is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oric Pharmaceuticals is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oric Pharmaceuticals has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.98% of the float of Oric Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oric Pharmaceuticals has a short interest ratio ("days to cover") of 4.8.
  • Change versus previous month

    Short interest in Oric Pharmaceuticals has recently decreased by 30.43%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Oric Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Oric Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Oric Pharmaceuticals has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 29 news articles for Oric Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for ORIC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oric Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,432,952.00 in company stock.

  • Percentage Held by Insiders

    5.70% of the stock of Oric Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    95.05% of the stock of Oric Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Oric Pharmaceuticals' insider trading history.
Receive ORIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oric Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ORIC Stock News Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
ORIC Pharmaceuticals (ORIC) Stock Price Target 2026
BTIG Research Reaffirms "Buy" Rating for Oric Pharmaceuticals (NASDAQ:ORIC)
See More Headlines

ORIC Stock Analysis - Frequently Asked Questions

Oric Pharmaceuticals' stock was trading at $8.18 at the start of the year. Since then, ORIC stock has decreased by 10.0% and is now trading at $7.36.

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) posted its quarterly earnings data on Monday, November, 16th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.05.

Oric Pharmaceuticals (ORIC) raised $112 million in an IPO on Friday, April 24th 2020. The company issued 7,500,000 shares at $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO.

Oric Pharmaceuticals' top institutional shareholders include State Street Corp (3.98%), Goldman Sachs Group Inc. (1.74%), Integral Health Asset Management LLC (1.64%) and Algert Global LLC (1.56%). Insiders that own company stock include Jacob Chacko, Dominic Piscitelli, Pratik S Multani and Angie You.
View institutional ownership trends
.

Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oric Pharmaceuticals investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), SoFi Technologies (SOFI), Viking Therapeutics (VKTX), Micron Technology (MU), Advanced Micro Devices (AMD) and Compass Pathways (CMPS).

Company Calendar

Last Earnings
11/16/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ORIC
CIK
1796280
Fax
N/A
Employees
111
Year Founded
2014

Price Target and Rating

High Price Target
$26.00
Low Price Target
$14.00
Potential Upside/Downside
+174.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$129.47 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-40.99%
Return on Assets
-38.54%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.09
Quick Ratio
13.19

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.28 per share
Price / Book
2.24

Miscellaneous

Outstanding Shares
103,653,000
Free Float
97,745,000
Market Cap
$762.89 million
Optionable
Optionable
Beta
1.23

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:ORIC) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners